These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9200338)

  • 1. Recombinant hirudin in the prevention of venous thromboembolism in patients undergoing elective hip surgery.
    Agnelli G; Sonaglia F
    Semin Thromb Hemost; 1997; 23(2):143-8. PubMed ID: 9200338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement.
    Eriksson BI; Kälebo P; Ekman S; Lindbratt S; Kerry R; Close P
    Thromb Haemost; 1994 Aug; 72(2):227-31. PubMed ID: 7831657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Low molecular weight heparins].
    Agnelli G; Cosmi B
    Medicina (Firenze); 1990; 10(1):9-15. PubMed ID: 2166209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hirudin for prophylaxis and treatment of deep vein thrombosis.
    Kemkes-Matthes B
    Semin Thromb Hemost; 2002 Oct; 28(5):455-8. PubMed ID: 12420241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of venous thromboembolic disease. The impact of low-molecular-weight heparin.
    Tapson VF; Hull RD
    Clin Chest Med; 1995 Jun; 16(2):281-94. PubMed ID: 7656540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hirudins for prophylaxis and treatment of venous thromboembolism.
    Prisco D; Falciani M; Antonucci E; Gensini GF
    Semin Thromb Hemost; 2001 Oct; 27(5):543-9. PubMed ID: 11668426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low molecular weight heparin: a critical analysis of clinical trials.
    Green D; Hirsh J; Heit J; Prins M; Davidson B; Lensing AW
    Pharmacol Rev; 1994 Mar; 46(1):89-109. PubMed ID: 8190751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low molecular weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results.
    Hirsh J; Crowther M
    Thromb Haemost; 1997 Jul; 78(1):689-92. PubMed ID: 9198240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep vein thrombosis prophylaxis in the outpatient setting: preventing complications following hospital discharge.
    Turpie AG
    Orthopedics; 1995 Jul; 18 Suppl():15-7. PubMed ID: 7479420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
    Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
    Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of venous thromboembolism in high-risk surgical and medical patients.
    Prandoni P; Sabbion P; Tanduo C; Errigo G; Zanon E; Bernardi E
    Semin Vasc Med; 2001; 1(1):61-70. PubMed ID: 15199515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-molecular-weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results.
    Crowther M; Hirsh J
    Semin Thromb Hemost; 1997; 23(1):77-81. PubMed ID: 9156414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
    Haas S
    Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.
    Tran AH; Lee G
    Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Low molecular heparin in prevention of thrombosis in orthopedic surgery].
    Jensen HP; Borris LC; Lassen MR; Sørensen JV; Rahr HB; Christiansen HM; Ejstrud P
    Ugeskr Laeger; 1993 Apr; 155(15):1109-15. PubMed ID: 8387708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Heparin-induced thrombocytopenia after elective hip joint replacement with postoperative prevention of thromboembolism with low-molecular-weight heparin].
    Marx A; Huhle G; Hoffmann U; Wang LC; Schüle B; Jani L; Harenberg J
    Z Orthop Ihre Grenzgeb; 1999; 137(6):536-9. PubMed ID: 10666863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative thrombosis prophylaxis with low molecular weight heparins in elective hip surgery. Clinical and economic considerations.
    Borris LC; Lassen MR; Jensen HP; Andersen BS; Poulsen KA
    Int J Clin Pharmacol Ther; 1994 May; 32(5):262-8. PubMed ID: 7921522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.
    Eriksson BI; Ekman S; Kalebo P; Zachrisson B; Bach D; Close P
    Lancet; 1996 Mar; 347(9002):635-9. PubMed ID: 8596376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement.
    Cofrancesco E; Cortellaro M; Leonardi P; Corradi A; Ravasi F; Bertocchi F
    Thromb Haemost; 1996 Mar; 75(3):407-11. PubMed ID: 8701398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.